ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
Update: 2025-11-05
Description
Featuring an interview with Prof Patrick Neven, including the following topics:
- Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00 )
- Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57 )
- Emerging data with novel oral SERD combinations (6:31 )
- Challenges for a general medical oncologist in breast cancer (8:41 )
- Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16 )
- Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16 )
Comments
In Channel























